Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2025: USD 1.89 B

Royalty Pharma plc EBITDA is USD 1.89 B for the Trailing 12 Months (TTM) ending June 30, 2025, a 31.27% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2024 was USD 1.44 B, a 134.20% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2023 was USD 615.67 M, a -46.75% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2022 was USD 1.16 B, a -38.99% change year over year.
  • Royalty Pharma plc EBITDA for the Trailing 12 Months (TTM) ending June 30, 2021 was USD 1.90 B, a -28.71% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)